IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Llinas-Brunet, M. et al

Appln. No.: Filed: For: To Be Accorded

March 5, 2002 Hepatitis C Inhibitor

Tri-Peptides

Docket No.:

Group Art Unit: 1626

Examiner:

Deborah C. Lambkin

#12

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents listed herein and on the attached PTO-1449 form and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies of the citations listed on the PTO-1449 form are filed in US Application No. 09/368,866, filed on August 5, 1999, Llinas-Brunet, M. et al (Attny. Docket No. 13/068).

The Examiner's attention is directed to co-pending U.S. Application No. 09/368,670, filed on August 5, 1999, Llinas-Brunet, M. et al (Attny. Docket No. 13/063-2-C2).

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4542 I hereby certify that this correspondence is being deposited with the U.S. Postal Service as express mail, airbill no. EV 051 684 953 US, in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on March 5, 2002

By: Philip I. Datlow Reg. No. 41,482